The short version
Only one company currently supplies this market — there is no backup if it stumbles.
The numbers behind every sentence are on this page below — and the Watch button emails you when any of them move.
ravulizumab · RAVULIZUMAB 300 mg/30mL · Solution, Concentrate · Intravenous · Alexion Pharmaceuticals Inc.
NDC 25682-0022-01 · 1 VIAL, GLASS in 1 CARTON / 30 mL in 1 VIAL, GLASS · BLA · View full market →
Only one company currently supplies this market — there is no backup if it stumbles.
The numbers behind every sentence are on this page below — and the Watch button emails you when any of them move.
No Medicare Part D plan in CMS's quarterly files lists this product. That usually means it is discontinued, a repackager's listing, or a product no plan has added to its formulary.
How Part D pricing works →No NADAC pricing on file for this NDC — NADAC covers drugs dispensed by retail community pharmacies.
Manufacturer list price as filed — not what pharmacies actually pay after discounts.
Not scored — fragility is computed for NADAC-priced NDCs.
There's no legal definition — it meets 3 of 6 public criteria. Why that matters →
No FDA shortage reports for this drug or its presentations.
No enforcement reports list this package NDC.
| Labeler | Strength | First seen | Last seen |
|---|---|---|---|
| Alexion Pharmaceuticals Inc. | RAVULIZUMAB 1100 mg/11mL | Jul 15, 2026 | Sep 2, 2026 |
| Alexion Pharmaceuticals Inc. | RAVULIZUMAB 300 mg/30mL | Jul 15, 2026 | Sep 2, 2026 |
| Alexion Pharmaceuticals Inc. | RAVULIZUMAB 300 mg/3mL | Jul 15, 2026 | Sep 2, 2026 |
Roster from daily NDC Directory diffs — first/last seen dates start July 2026.
DrugDashboards, "Ultomiris — NDC 25682-0022-01," retrieved September 3, 2026, https://drugdashboards.com/drug/25682002201.
Free to cite with attribution — see how the data is put together.